Vericel Corporation VCEL

US Biotechnology

$58.37 ▼ -0.03% ($-0.02)

Open $58.49

Prev Close $58.39

Day Range $57.81 – $59.35

52W Range $28.95 – $59.48

Market Cap $2.06B

P/E (TTM) 121.04

Beta 1.01

EPS (TTM) $0.42

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1997-02-04
Shares Out.	51,210,000
Website	vcel.com/ ↗
Phone	17349305555
Employees	398
Revenue	$85.4M
Gross Profit	$62.6M
Net Income	$14.2M
Free Cash Flow	$57.9M
Total Assets	$517.1M
Total Liabilities	$132.9M
Equity	$384.2M

About Vericel Corporation

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Vericel Corporation is a publicly traded company under the ticker symbol VCEL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.